TriSalus Q4 revenue $13.2M (+60% YoY); reaffirms 2026 revenue guidance $60-62M

TriSalus Life Sciences, Inc.

Full-year 2025 revenue $45.2M (+53% YoY); Q4 gross margin 86.7% vs 85.3% prior year.
Adjusted EBITDA loss improved to $0.9M in Q4 2025 from $5.7M loss in Q4 2024.
Net loss attributable to common shareholders FY2025 $69.7M ($1.84 loss per share) vs $33.2M ($1.31) prior year.
Raised $46M gross proceeds from public offering post-Q4; cash and equivalents $20.4M at Dec 31, 2025.
Appointed Michael Stansky to board in Feb 2026; launched TriNav XP infusion system.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TriSalus Life Sciences, Inc. reported 2026 results: revenue $60 million to $62 million. Guidance reaffirmed.

Period: 2026
Revenue: $60 million to $62 million
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

Reaffirms 2026 Revenue Guidance of $60-62 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TriSalus Life Sciences, Inc. reported the year ended December 31, 2025 results: revenue $45.2 million, net income $69.7 million, EPS $1.84.

Period: the year ended December 31, 2025
Revenue: $45.2 million
Net income: $69.7 million
EPS: $1.84
Result: reported results

Exact text from the filing

Revenue, all from sales of the TriNav system, was $45.2 million for the year ended December 31, 2025, an increase of 53% compared to the same period in 2024.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TriSalus Life Sciences, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $13.2 million.

Period: the fourth quarter ended December 31, 2025
Revenue: $13.2 million
Result: reported results

Exact text from the filing

Generated $13.2 million in net sales, a 60% increase year-over-year

View on SEC.gov

50 earnings releases filed in the last 30 days. Browse all earnings releases →

TriSalus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-015155

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.